

# UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR 09/669,301 09/25/00 KUDLICKI 10022802/AMB **EXAMINER** HM22/0914 FULBRIGHT & JAWORSKI LLP PAPER NUMBER **ART UNIT** 600 CONGRESS AVENUE SUITE 2400 AUSTIN TX 78701 1655 DATE MAILED:

(X)

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

09/14/01

## Office Action Summary

Application No. 09/669,301

Examiner

Arun Chakrabarti

Art Unit 1655

Kudlicki

	The MAILING DATE of this communication appear	rs on the cover sheet with the correspondence address
A SH THE I	for Reply ORTENED STATUTORY PERIOD FOR REPLY IS SE MAILING DATE OF THIS COMMUNICATION.	,
af - If the be - If NC co	ter SIX (6) MONTHS from the mailing date of this communate period for reply specified above is less than thirty (30) date considered timely.  It is period for reply is specified above, the maximum statutor immunication.	CFR 1.136 (a). In no event, however, may a reply be timely filed nication. ys, a reply within the statutory minimum of thirty (30) days will y period will apply and will expire SIX (6) MONTHS from the mailing date of this by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any	reply received by the Office later than three months after t rrned patent term adjustment. See 37 CFR 1.704(b).	the mailing date of this communication, even if timely filed, may reduce any
Status		
11 🗶	Responsive to communication(s) filed on May 7,	2001 .
2a) 🗌	This action is <b>FINAL</b> . 2b) 🔀 This a	action is non-final.
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.	
Disposi	tion of Claims	
4) 💢	Claim(s) <u>1-50</u>	is/are pending in the application.
- 4	4a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
<i>6)</i> $\square$	Claim(s)	is/are rejected.
71 🗆	Claim(s)	is/are objected to.
8) 💢	Claims 1-50	are subject to restriction and/or election requirement.
Applica	ition Papers	
91 🗆	The specification is objected to by the Examiner.	
10)	The drawing(s) filed onis/a	
11)	The proposed drawing correction filed on is: a) $\square$ approved b) $\square$ disapproved.	
12)	The oath or declaration is objected to by the Exa	miner.
13)	under 35 U.S.C. § 119  Acknowledgement is made of a claim for foreign  All bl  Some* cl  None of:	
	<ol> <li>Certified copies of the priority documents h</li> <li>Certified copies of the priority documents h</li> </ol>	
	3. Copies of the certified copies of the priority application from the International Bu	documents have been received in this National Stage reau (PCT Rule 17.2(a)).
*S	ee the attached detailed Office action for a list of	
14)	Acknowledgement is made of a claim for domes	tic priority under 35 U.S.C. § 119(e).
Attachm	ent(s)	
15) 🔲 N	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
-	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
171 /	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:

Application/Control Number: 09/669,301 Page 2

Art Unit: 1655

1

#### **DETAILED ACTION**

#### Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1-23 and 37-49, drawn to method of inhibiting the nuclease enzyme, classified in class 422, subclass 40.
  - II. Claims 24-36 and 50, drawn to a solution comprising inhibitor of nuclease, classified in class 252, subclass 380+.
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions of Groups I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process of inhibiting nuclease of Group I can be practiced with inhibitor of Group II or by DEPC or by high temperature.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. A telephone call was made to Mark Wilson on September 6, 2001, to request an oral election to the above restriction requirement, but did not result in an election being made.

Art Unit:

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CAR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CAR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CAR 1.48(b) and by the fee required under 37 CAR 1.17(I).

### Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph. D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-7401. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Arun Chakrabarti,

Patent Examiner

September 7, 2001

JEFFREY FREDMAN